NCT02250300View on ClinicalTrials.gov

MLN9708 for the Prophylaxis of Chronic Graft-versus-host Disease in Patient Undergoing Allogeneic Transplantation

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 19, 2014

Primary Completion Date

October 6, 2020

Study Completion Date

October 6, 2020

Conditions

Allogeneic Hematopoietic Stem Cell Transplantation

Interventions

DRUG

MLN9708 (2.3 mg)

2.3 mg

DRUG

MLN9708 (4.0 mg)

4.0 mg

DRUG

MLN9708 (3.0 mg)

3.0 mg

Trial Locations (1)

53226

Froedtert Hospital and the Medical College of Wisconsin, Milwaukee

All Listed Sponsors

lead

Mehdi Hamadani

OTHER

NCT02250300 - MLN9708 for the Prophylaxis of Chronic Graft-versus-host Disease in Patient Undergoing Allogeneic Transplantation | Biotech Hunter | Biotech Hunter